Please login to the form below
chemotherapy
This page shows the latest chemotherapy news and features for those working in and with pharma, biotech and healthcare.
AZ’s immuno-oncology combo fails another lung cancer trial
achieved a “clinically meaningful reduction in the risk of death compared to chemotherapy”, although the trial wasn’t powered to detect statistical significance. ... which has not spread widely around the body after platinum chemotherapy or
Latest news
-
Merck’s Keytruda meets survival challenge in NSCLC
Almost 70% of patients on the combination were still alive after 12 months, compared to 49% of the chemotherapy group. ... the response rate compared to chemotherapy in first-line NSCLC patients with a high tumour mutation burden (TMB).
-
BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer
on Keytruda (pembrolizumab) plus chemotherapy in this setting.
-
Merck’s Keytruda scores in frontline lung cancer yet again
In January, the drug become the drug in the PD-1/PD-L1 class to improve overall survival when given in combination with chemotherapy in previously-untreated patients in the ... Roche’s Impower150 study of PD-L1 inhibitor Tecentriq (atezolizumab) plus
-
Incyte/Merck trial failure bodes ill for IDO class
That means for now, PD1/PD-L1 inhibitors as monotherapy, or combined with chemotherapy or CTLA4 drugs like BMS’Yervoy (ipilimumab) “may end up continuing to be the dominant regimens”.
-
Another Tecentriq win for Roche as Avastin combo boosts survival
chemotherapy. The Swiss pharma group reported a 38% improvement in progression-free survival (PFS) data in the IMpower150 trial of Tecentriq (atezolizumab) and Avastin (bevacizumab) in non-small cell lung cancer ... The 1, 200 patient trial compared
More from news
Approximately 6 fully matching, plus 775 partially matching documents found.
Latest Intelligence
-
The threat of antimicrobial resistance
After all, so many of today’s life-saving healthcare advances, from cancer chemotherapy to heart surgery, rely on effective antibiotics being available to prevent infections in patients.
-
Taking a lean and careful approach
Chemotherapy and Pharmacology, which concluded its treatment regimen showed ‘encouraging clinical benefit’.
-
Reactivating drug research programmes
In the case of cancer treatment, such drugs could also help to limit the use of traditional chemotherapy, which can be costly and have undesirable side effects.
-
Deal Watch February 2017
As an ADC IMMU-132 contains SN-38, which is the active metabolite of the chemotherapy agent irinotecan, conjugated to an anti-TROP-2 antibody.
-
Deal Watch November 2016
were thought to be a result of the chemotherapy regimen used to prepare the patients before administering the CAR T cell therapy.
More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Dr Sotirios Stergiopoulos leaves Shire for Ipsen
affairs strategies and a strong expertise in oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumour indications.
-
BMS appoints oncology development head
Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions
-
AP Pharma overhauls senior management team
AP Pharma's lead product APF530 for the prevention of chemotherapy-induced nausea and vomiting.
-
AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales
AP Pharma appoints Dendreon’ s Jesse Hollingsworth to lead sales. Joins as company prepares to advance APF350 to treat side effects of chemotherapy. ... The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
Bayer’ s former oncology head Robert Rosen joins AP Pharma. Will lead launch of drug to prevent chemotherapy-induced nausea. ... In this role he will lead efforts at the US-based specialty pharma company to launch APF530 – AP Pharma's lead product
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
CASE STUDY: Creation of Global Value Dossiers for a US-based Global Pharmaceutical Company
Febrile Neutropenia (FN) during adjuvant chemotherapy is associated with significant morbidity, mortality risk, and incremental costs. ... The client wanted a vendor to develop content for a Global Value Dossier (GVD) about the burden of febrile
-
Virtual reality—a change for the better in medical education
Virtual reality as a distraction intervention for women receiving chemotherapy. Oncol Nurs Forum. ... 2012; 181:53– 7. Schneider SM, Kisby CK, Flint EP. Effect of virtual reality on time perception in patients receiving chemotherapy.
-
Forecasting in Dynamic Oncology Markets
future. Industry commentators believe immuno-oncology to be the third major breakthrough in cancer treatment, following the early days of chemotherapy and the targeted treatments that followed on from them. ... Only by combining with traditional
-
Immunotherapy in oncology
This is very different to how we currently assess chemotherapies – by their response rates – where stable disease would be perceived as a poor response.
-
Innovation in pharma: the highs and lows of the current healthcare economy
Also in cancers: chimeric antigen receptor T cell (CAR-T) therapy, a type of cancer immunology that could dismiss chemotherapy in some cancers, is now licensed in the US.
More from PMHub
Approximately 0 fully matching, plus 14 partially matching documents found.
Featured jobs
-
Senior Programme Executive
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
-
Senior Medical Writer
-
Great salary and benefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Scientific Director
-
Great salary and bebefits
- Account Manager – Med Comms – London
-
Salary TBC
-
Senior Medical Writer
-
Great salary and bebefits
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
Subscribe to our email news alerts
- Shire warms to Takeda’s latest offer, extending deadline
- Otsuka finally gets FDA OK for kidney disease drug
- Pfizer takes aim at UK’s health tech industry
- Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more
- It’s nice, but it’s not an infographic
- PureTech Health appoints new chief financial officer
PMHub
infill healthcare communication
infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
